Skip to main content
Advertising

Originally published February 3, 2014 at 3:05 PM | Page modified February 3, 2014 at 6:11 PM

  • Share:
           
  • Comments (0)
  • Print

Seattle biotech Acucela sets terms of Japanese IPO

Acucela said the underwriters of its initial public offering in Japan will sell 9.2 million shares at $17.65 apiece, raising about $143 million after expenses and discounts.


By Seattle Times business staff

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

Seattle biotechnology company Acucela said the underwriters of its initial public offering in Japan will sell 9.2 million shares at $17.65 apiece, raising about $143 million after expenses and discounts.

The shares, which are not available to U.S. investors and won’t be traded here, have been approved for listing on the the Mothers market of the Tokyo Stock Exchange, Acucela said in a regulatory filing.

The Japanese underwriters will pay Acucela by Feb. 12 and have an option to buy up to 1.38 million additional shares from Acucela founder and chief executive officer Ryo Kubota, the filing said.

Acucela, based in downtown Seattle, is developing therapeutics to treat or slow the progression of sight-threatening ophthalmic diseases. Late last year it announced plans to cut 35 percent of its work force after Otsuka, its major drug-company partner, dropped co-development of one drug candidate when Phase III results proved disappointing.



News where, when and how you want it

Email Icon

Get ready for 2015

Get ready for 2015

The Seattle Times 12-month wall calendar features hand-picked photos of life in the Pacific Northwest. Order while supplies last!

Advertising

Advertising


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►